Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Radiation Oncology
•
Thoracic Malignancies
•
Medical Oncology
How often, if ever, do patients with initially negative targetable mutation workup become positive later in recurrent lung cancer?
Related Questions
In ES-SCLC presenting with extensive brain metastases, how do you time whole brain radiation after the first cycle of chemotherapy has already been delivered?
Would you offer consolidative radiotherapy for oligometastatic NSCLC?
What would be your approach in a patient who presented with a solitary brain metastasis that resolved after chemo without local therapy?
Is there a role for nintedanib in the management of patients with radiation-induced pulmonary fibrosis?
How do you treat Stage IIIC T4N3 NSCLC?
Do you still offer adjuvant chemotherapy and chemoradiation for NSCLC after neoadjuvant chemoimmunotherapy?
What is your approach to radiographically suspicious lung nodules for which initial biopsy was negative for malignancy?
Did NRG LU004 demonstrate safety with hypofractionated lung radiation and concurrent ICI?
Will you consider definitive concurrent chemoradiation for stage IV lung adenocarcinoma with metastasis limited to an internal mammary lymph node?
What systemic therapy would you offer to a patient with metastatic EGFR exon 19 deleted NSCLC to the brain with isolated CNS progression while on osimertinib 80 mg and progressed through WBRT?
